A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
Recruiting now
Conditions studied: Type 2 Diabetes
In brief
The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy
Key facts
- Study ID
- NCT06649162
- Run by
- Boryung Pharmaceutical Co., Ltd
- People needed
- 10000
- Starts
- 2024-09-30
- Expected to finish
- 2027-03-01
- Last updated by the study team
- 2024-10-18
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1)
- Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study.
You may not qualify if…
- Those who have a history of taking a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1).
- Those who are expected to need insulin prescription during the study period.
Where it is running
- Andong Hospital — Andong, Gyeongsangbuk-do, South Korea (enrolling)
- Konkuk University medical center — Seoul, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.